Dukagjin Blakaj | Oncology | Best Researcher Award

Published on by Best Achievements

Prof. Dr. Dukagjin Blakaj | Oncology | Best Researcher Award

Prof. Dr. Dukagjin Blakaj, The Ohio State University,  United States.

Dr. Dukagjin M. Blakaj is a visionary leader in radiation oncology, currently serving as the Drs. Malati and Ganesh Potdar Endowed Professor and Vice Chair of Clinical Operations at The Ohio State University Comprehensive Cancer Center. Renowned for advancing proton therapy and translational cancer research, he has overseen exponential growth in departmental faculty, revenue, and NIH funding since joining in 2013. His leadership has transformed clinical operations, implemented strategic innovations, and significantly expanded clinical trial participation. Dr. Blakaj has mentored numerous faculty and fellows, initiated multi-disciplinary research collaborations, and secured millions in philanthropic and research funding. An influential educator and administrator, he also directs fellowships in Head & Neck, CNS/Pediatric, and IORT radiation oncology. Beyond his institutional impact, he serves on national committees and journal boards, shaping the future of cancer research and care. His work exemplifies excellence in clinical innovation, academic mentorship, and collaborative leadership across the oncology landscape.

Profile

Scopus Profile

Orcid Profile

Google Scholar Profile

Education

Dr. Dukagjin Blakaj holds a distinguished academic background with dual advanced degrees in medicine and science. He earned his M.D. and Ph.D. in Biochemistry from the Albert Einstein College of Medicine, where he also completed a Master of Science in Biochemistry. Prior to that, he obtained both his Master of Arts and Bachelor of Arts degrees in Chemistry and Molecular Biology & Biophysics from Wesleyan University. His academic excellence is reflected in numerous accolades, including the Rudin Scholarship and Dean’s Recognition Award. He completed his internship in internal medicine at Mount Sinai Beth Israel Medical Center and a residency in radiation oncology at Montefiore-Einstein Comprehensive Cancer Center. Further, he undertook a post-doctoral fellowship focused on HPV epidemiology and therapeutic vaccine development. Dr. Blakaj’s academic training is complemented by multiple faculty leadership and coaching certifications, which have equipped him with the strategic and educational tools to excel as a clinical and academic leader in oncology.

Experience

With over a decade of experience at The Ohio State University Comprehensive Cancer Center, Dr. Dukagjin Blakaj has held progressive leadership roles, including Director of Head & Neck/Skull Base Division, Director of Clinical Operations, and currently Vice Chair of Clinical Operations. Under his guidance, the department expanded from 13 to 51 faculty members, increased revenue by over 450%, and tripled NIH funding. He has played a pivotal role in enhancing operational efficiencies, developing data lakes for research, and implementing standardized procedures across divisions. As a fellowship director in multiple subspecialties, he has trained future leaders in radiation oncology. His innovative leadership has advanced FLASH radiotherapy, Theranostics, and multidisciplinary care models. Dr. Blakaj also serves as Co-PI on several clinical trials and large-scale grants, leading to substantial contributions in patient care and translational research. His collaborative, data-driven approach continues to drive excellence in academic medicine and clinical cancer care.

Research Interests

Dr. Dukagjin Blakaj’s research spans translational oncology, radiation therapy innovations, and molecular mechanisms of treatment resistance. He focuses extensively on head and neck, skull base, and spine malignancies, leading efforts to develop precision radiation protocols and novel therapeutic strategies. His research has garnered over $5 million in funding, supporting groundbreaking clinical trials, including studies on FLASH radiotherapy, immunotherapy combinations, and stereotactic treatments. He is Principal or Co-Investigator on numerous NIH, industry-sponsored, and institutional grants addressing treatment optimization, radio-sensitization, and rare cancer biology. His work includes building large-scale clinical databases and integrating radiomic and molecular data into patient care models. He co-leads the PARTNER protocol to create a comprehensive data lake for translational research. His commitment to collaborative research has elevated institutional trial accruals and contributed to over 200 peer-reviewed publications. Through mentorship, innovation, and cross-disciplinary collaboration, Dr. Blakaj is advancing personalized oncologic care on both clinical and molecular fronts.

Awards and Honors

Dr. Dukagjin Blakaj has received numerous prestigious awards recognizing his contributions to oncology, research, and education. Notably, he received the James Outstanding Physician Peer Award for his leadership, professionalism, and collaborative spirit. He has consistently ranked among the top 10% of most published and cited doctors on Doximity (2021–2024) and was named a Top Doctor nationally in 2021. His article in Practical Radiation Oncology was selected for Elsevier’s Head & Neck Cancer Awareness Month feature. Additional accolades include the Best Teacher Award at the Osler Board Review Course, the Samuel J. Roessler Memorial Scholarship, and multiple abstract and travel awards from ASTRO, ACRO, and other leading organizations. He was also a finalist for the 2021 International Book Awards for his leadership publication. His early academic excellence was recognized through fellowships from the American Heart Association, Howard Hughes Medical Institute, and the International Biophysical Society, setting the foundation for his distinguished career.

 Publications Top Notes

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)

Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer

Time to surgery and survival in head and neck cancer

Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

NRG-HN002: a randomized phase II trial for patients with p16-positive, non-smoking-associated, locoregionally advanced oropharyngeal cancer

Single-isocenter multitarget stereotactic radiosurgery is safe and effective in the treatment of multiple brain metastases

Molecular dynamics and thermodynamics of protein−RNA interactions: Mutation of a conserved aromatic residue modifies stacking interactions and structural adaptation in the U1A protein

Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study

Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies

A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma

Evolutionary and biophysical relationships among the papillomavirus E2 proteins

Emerging concepts and novel strategies in radiation therapy for laryngeal cancer management

A digital twin for simulating the vertebroplasty procedure and its impact on mechanical stability of vertebra in cancer patients

Conclusion

Dr. Dukagjin M. Blakaj stands as a leading force in academic radiation oncology, seamlessly integrating clinical excellence, visionary leadership, and groundbreaking research. His transformative impact at The Ohio State University has resulted in institutional growth, enriched patient care, and elevated academic standards. A dedicated mentor and educator, he has cultivated the next generation of oncology leaders through innovative fellowships and global mentorship. His expansive research portfolio spans molecular biology, clinical trials, and AI-driven data analysis, reflecting a commitment to precision medicine and translational impact. Recognized nationally and internationally for his achievements, Dr. Blakaj continues to shape the future of radiation oncology through strategic leadership, collaborative partnerships, and compassionate care. His efforts exemplify how visionary thinking, paired with operational excellence, can revolutionize patient outcomes and institutional success. Dr. Blakaj remains a beacon of excellence in medicine, embodying the ideals of academic leadership, research innovation, and unwavering dedication to improving human health.

Yudai Shimojukkoku | Oncology | Best Researcher Award

Published on by Best Achievements

Dr. Yudai Shimojukkoku | Oncology | Best Researcher Award

Dr. Yudai Shimojukkoku, Saitama Cancer Center, Japan.

Dr. Shimojukkoku Yudai 🧑‍🔬 is a dedicated cancer researcher at Saitama Cancer Center and Kagoshima University. His work focuses on oral squamous cell carcinoma, exploring the tumor microenvironment and identifying novel biomarkers 🧫. He collaborates with renowned experts like Prof. Sasahira, advancing both basic and clinical research. His contributions aim to bridge the gap between oral health and systemic diseases such as diabetes 🦷❤️. Dr. Yudai’s research is paving the way for innovative cancer diagnostics and treatments. 🌟

Profile

SCOPUS ID

🎓 Early Academic Pursuits

Dr. Shimojukkoku Yudai embarked on his academic journey with a deep-rooted passion for medical sciences, particularly in oncology. He demonstrated an early commitment to understanding the biological mechanisms of cancer, eventually focusing his expertise on oral squamous cell carcinoma. His educational background provided a strong foundation in both clinical and molecular pathology, setting the stage for a career centered on bridging lab-based discoveries with real-world clinical applications.

💼 Professional Endeavors

Currently affiliated with the Saitama Cancer Center and Kagoshima University’s Department of Molecular and Oral Pathology, Dr. Yudai combines research with clinical responsibilities. He is deeply involved in improving diagnostic techniques and therapeutic approaches in oral cancer. His daily work integrates patient-centered care with experimental exploration, ensuring translational relevance of his research.

🔬 Contributions and Research Focus On Oncology 

Dr. Yudai’s research targets the tumor microenvironment and identification of novel biomarkers in oral cancer. He has led and participated in both in vitro and in vivo studies, as well as computational analyses (in silico) to discover two previously unidentified markers that have since influenced ongoing investigative studies. His active collaboration with renowned cancer researcher Prof. Sasahira has further enhanced his research on the link between oral cancer and periodontal disease, and the complex relationship between cancer progression and diabetes mellitus.

🌍 Impact and Influence

Although early in his career, Dr. Yudai’s work has begun to leave a significant impact in the field of oral oncology. His insights are contributing to the evolving understanding of how systemic diseases and oral cancer interact. His research, while currently limited in citation due to its recent publication, presents promising implications for clinical diagnostics and personalized cancer therapy. His focus on translational outcomes ensures his findings are poised to improve patient outcomes in the near future.

🧠 Research Skills

Dr. Yudai demonstrates a versatile skill set encompassing molecular biology, histopathology, bioinformatics, and clinical oncology. He is adept at designing and executing comprehensive experimental workflows and data interpretation. His capacity to blend clinical insights with molecular discoveries makes him a valuable asset in precision medicine research.

🏅 Awards and Honors

Dr. Yudai is actively seeking recognition in categories such as the Young Scientist Award, Best Researcher Award, Outstanding Scientist Award, and Best Research Scholar Award. His self-motivated dedication, impactful publications, and meaningful collaborations make him a strong contender for these accolades. His contributions signify excellence in early-stage cancer research.

🏛️ Legacy and Future Contributions

As he advances, Dr. Yudai aims to pioneer new diagnostic tools and therapeutic targets that can revolutionize the treatment of oral cancers. His collaborative spirit and interdisciplinary research vision promise continued contributions to global cancer research. With a commitment to both innovation and patient care, he is laying a foundation that could influence generations of oncological practice and research.

Publications Top Notes

📘 Title: MCTP2 is a novel biomarker promoting tumor progression and nodal metastasis in oral squamous cell carcinoma
🧑‍🔬 Authors: Shimojukkoku Yudai, et al.
📚 Journal: Scientific Reports
📅 Year: 2025
🔗 Link: https://www.nature.com/articles/s41598-025-02094-9 (🔒 Currently disabled)
🧬 Highlights: Introduces MCTP2 as a promising biomarker for tumor progression and nodal metastasis in oral squamous cell carcinoma.

 

Yvonne Rosenberg | Cancer | Best Researcher Award

Published on by Best Achievements

Dr. Yvonne Rosenberg | Cancer | Best Researcher Award

Dr. Yvonne Rosenberg,PlantVax Inc, United States.

🌿 Dr. Yvonne J. Rosenberg is the CEO of PlantVax Inc. and a leading expert in immunology and biotherapeutic innovation. With a Ph.D. from Australian National University, she has pioneered research in HIV immunotherapy, autoimmunity, and nerve agent antidotes. 🌍 Her work bridges basic science and translational medicine, using plant-based systems to produce cutting-edge therapies. 💉 With decades of global recognition and impactful publications, she continues to revolutionize the field of biomedical science. 🧬

Profile

Scopus profile

Orcid Profile

🎓 Early Academic Pursuits

Yvonne J. Rosenberg began her academic journey at the University of Queensland, Australia, earning a B.Sc. in Zoology (1969) and a First-Class Honours B.Sc. in Parasitology (1970). She continued to develop her scientific expertise with a Ph.D. in Immunology from Australian National University in 1976. Her foundational academic training provided a robust framework in parasitology and immunological mechanisms. Rosenberg further honed her expertise as a Visiting Fellow at the National Institutes of Health (NIH), where she focused on advanced immunological research. 🎓🔬

💼 Professional Endeavors

Dr. Rosenberg’s professional journey spans academia, industry, and biotech leadership. From her early roles as a Visiting Scientist in London to research positions at NIH and Columbia University, she moved into leadership roles at TherImmune Research Corp and ProCell Corporation. In 2007, she founded PlantVax Inc, where she currently serves as CEO. Her work reflects a seamless blend of translational research and product innovation across fields such as HIV, autoimmune disease, and biodefense. 🏢🌿

🔬 Contributions and Research Focus On Cancer 

Dr. Rosenberg’s research contributions are vast and groundbreaking. Her early work on B lymphocyte development and T cell regulation laid the groundwork for major advancements in immunology and parasitology. She transitioned into HIV pathogenesis research, utilizing macaque models to study immune responses. More recently, her focus has shifted to the development of recombinant therapeutic molecules, including broadly neutralizing HIV antibodies (bnAbs) and plant-derived cholinesterases for neurotoxin defense. 🌱🧪

🌍 Impact and Influence

Dr. Rosenberg’s research has directly impacted fields ranging from infectious diseases to neuroprotection, influencing therapeutic approaches and policy directions in HIV, autoimmunity, and biodefense. Her innovative plant-based expression systems offer cost-effective solutions with global health applications, making her work especially relevant in low-resource settings. Her translational focus has brought lab innovations closer to real-world implementation. 💡🌐

🧠 Research Skills

Dr. Rosenberg possesses expertise in molecular immunology, plant-based protein expression, animal modeling, vaccine development, and biochemical pharmacology. Her ability to translate basic research into applied therapies demonstrates her proficiency in both exploratory science and product development. Her skills extend to leadership in collaborative, interdisciplinary research initiatives. 🧬🧫

🏅 Awards and Honors

Dr. Rosenberg’s exceptional achievements have been recognized with numerous awards, including the NIH Fogarty Award, NHMRC CJ Martin Biomedical Award, and American Association of Immunologists Travel Awards. These accolades underscore her influence and sustained contributions to biomedical research at the global level. 🥇🌟

🏛️ Legacy and Future Contributions

With a career spanning decades, Dr. Rosenberg’s legacy lies in her interdisciplinary approach—blending basic immunology with translational innovation. Her pioneering use of plant systems for protein production is likely to shape the future of vaccine and therapeutic development. As she continues her leadership at PlantVax, her work promises to drive forward solutions for HIV prevention, autoimmune treatment, and chemical threat mitigation. Her contributions will resonate through both scientific literature and lifesaving applications for years to come. 🚀🌿

Publications Top Notes

📄 1. A single post-exposure oxime RS194B treatment rapidly reactivates acetylcholinesterase and reverses acute symptoms in macaques exposed to diethylphosphorothioate parathion and chlorpyrifos insecticides
📰 Journal: Journal of Neurochemistry
📅 Year: 2024
🔢 Citations: 4
🧪 Topic: Organophosphate poisoning, macaque model, oxime therapy

📄 2. The impact of solvents on the toxicity of the banned parathion insecticide
📰 Journal: Chemico-Biological Interactions
📅 Year: 2023
🔢 Citations: 3
🧪 Topic: Parathion insecticide, solvent effects, toxicology

📄 3. Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
📰 Journal: mBio
📅 Year: 2023
🔢 Citations: 8
🧬 Topic: Immunoglobulin transport, placental biology, Fc receptors